Items tagged with Scientific research

Research led by Colorado State University reveals promising strategy for treating tuberculosis (post)

FORT COLLINS - Research at Colorado State University reveals that even the most intractable cases of tuberculosis might be effectively battled with a new drug cocktail combining conventional antibiotics and nontoxic compounds that mimic those found in some sea sponges.

Dartmouth and Aeras join forces to conduct study of new tuberculosis vaccine (post)

Hanover, NH and Rockville, MD, March 19, 2014 – Dartmouth’s Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world’s deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial.

Fighting antibiotic resistance with ‘molecular drill bits’ (post)

DALLAS, March 17, 2014 — In response to drug-resistant “superbugs” that send millions of people to hospitals around the world, scientists are building tiny, “molecular drill bits” that kill bacteria by bursting through their protective cell walls. They presented some of the latest developments on these drill bits, better known to scientists as antimicrobial peptides (AMPs), at the 247th National Meeting & Exposition of the American Chemical Society (ACS), the world’s largest scientific society.

Japanese fund awards $12 million to develop innovative tools for Chagas disease, schistosomiasis, parasitic roundworms and TB (post)

TOKYO, JAPAN (March 20, 2014)—The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms. GHIT also announced a second round of funding of US$5.65 million for a novel vaccine candidate for tuberculosis and unveiled a new investment program that will help researchers find the most promising new drug candidates to battle these and other infectious diseases.

Otsuka and The Union announce Global TB Research & Innovation Award (post)

-- Program fosters young leaders in TB research

-- Honorees will receive grant to attend international training in TB control strategies and showcase their research at the 45th Union World Conference on Lung Health

Film highlights TB epidemic in China and China’s crucial role in eliminating TB worldwide (post)

March 21, 2014 – Beijing, China - A short documentary film exploring the tuberculosis (TB) epidemic in China has been launched by Aeras, a nonprofit biotech advancing tuberculosis vaccines for the world. “Hope: Developing Safe and Effective Vaccines to Fight TB” highlights China’s desire and innovative leadership in solving the global problem of TB. The film includes Chinese researchers who are leading the way in developing new vaccines to prevent tuberculosis. Featuring patients, doctors and top TB vaccine researchers, Hope illuminates China’s unique role in ending the global tuberculosis epidemic.

KwaZulu-Natal Research Institute and IBM Research fight tuberculosis in South Africa (post)

DURBAN, South Africa. 24 March 2014: On World Tuberculosis Day, IBM and the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) have announced plans to research new treatment approaches to fight tuberculosis (TB) in South Africa. IBM’s Big Data analytics technologies will be put to work on bacterial genetics and drug susceptibility tests to better understand the genomic mechanisms that cause resistance to antibiotics. The ultimate goal is to find new treatments and diagnostic approaches to fight TB.

IDRI receives $3.4 million grant extension for TB drug discovery (post)

SEATTLE, March 24, 2014: IDRI's drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million. The grant is focused on identifying new leads and drug targets for tuberculosis with the ultimate goal of producing new drugs to treat TB.

Fundamental research is the key to eliminating TB (post)

Fewer people will contract tuberculosis (TB) this year than last. That is good news, and enough to meet the United Nations Millennium Development Goal that called “to halt and begin to reverse the incidence” of TB. But the pace of progress is too slow. Some 8.6 million people contracted the disease in 2012, and 1.3 million died, including 320,000 people with HIV. As it stands, the world will miss the international target to eliminate TB by 2050. To meet that ambitious goal, we need to modernize the way in which we tackle the disease. This means that fundamental research must play a bigger part in nurturing the development of diagnostics, medicines and vaccines.

Multitarget TB drug could treat other diseases, evade resistance (post)

CHAMPAIGN, Ill. — A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a study by University of Illinois chemists and collaborators.

Page 2 of 29 · Total posts: 0

←First 1 2 3 Last→